National Yang Ming University Business Center of Industry-Academia Liaison Serial Events of Bio-navigator -- Corporate Keynote Speech
Establishment of an Exclusive Platform for Biotech Unicorns
Chief Executive Officer Today Su at Golden Biotechnology Corp. started a series of lively and penetrating speeches on the theme of biotech unicorns.
Chief Executive Officer Today Su at Golden Biotechnology Corp., a biotechnology company showing outstanding achievement in small molecule drug research and development, was invited to the Bio-Navigator Lecture in July. With his unique, rich experiences and opinions, Chief Executive Officer Su revealed some concepts for the promotion of biotech industry development that were different from those in the past, expecting the emergence of the next biotech unicorn. His unique and sensational perspectives have brought more innovative inspirations to the audience.
Chief Executive Officer Su has once conducted a clinical experiment in Europe for more than four years. By accident, he discovered that Europeans’ working pattern is very different from Asians’. Europeans may work as a consultant in a one-person company, whereas Asians tend to work for only one company in a lifetime. However, it is hard to keep a job permanently in this ever-changing era, accompanied by the emergence of artificial intelligence (AI). He reckons that you will have a more purposeful and valuable life if there is a more systemic method that allows you to contribute your expertise and have flexible hours to do the job that you love. This idea has consequently brought the concept of LinkingPros Platform to life, linking professionals in the industry together to provide more complete and professional consulting services.
A full house at the lecture, which took the audience by storm.
To establish a biotech consulting platform, claimed Chief Executive Officer Su, we should invite biotech talents to join the platform and select integrated clinical research data to input into the platform. Only in this way, we can accumulate abundant and complete clinical outcomes and provide suitable products for the biotech industry. Successful establishment of this systemic platform can rapidly help us select suitable research and development products and build an industrial network, leading us to find the biotech unicorn with the highest potential.
Vice-President Hsieh gave recognition to Chief Executive Officer Su’s idea regarding the successful system, and presented him with a certificate of appreciation after the lecture.
Several professors and students have inquired about the platform with enthusiasm. For instance, Director Ueng-Cheng Yang at the National Yang-Ming University Center for Systems and Synthetic Biology was very interested in how the platform selects talents and assists the biotech industry in creating development strategies. Chairperson Tzu-Hao Cheng at the Institute of Biochemistry and Molecular Biology inquired about the differences between this platform and the platforms that other countries currently use. Chief Executive Officer Su replied that the platform primarily aims to provide solutions regarding the industry to the investors/funders. They will now focus on the talents from the talent pool expertized in clinical trials. The size of the talent pool will expand through recommendations, and this is done to optimize the quality of the talent pool. At the current stage, the scope of this platform is far smaller than those similar platforms used overseas. So, for now, we can first cooperate with these overseas platforms to train ourselves in platform development and build our own platform interpersonal network.
A photograph was taken after the lecture for (from the left): Chairperson Tzu-Hao Cheng at the Institute of Biochemistry and Molecular Biology, Vice-President Yu-Te Wu of Research & Development, Vice-President Jen-Chuen Hsieh, Chief Executive Officer Today Su, Chief Executive Officer Hsien-Chih Pei of Center for Academia and Industry Collaboration, and Director Ueng-Cheng Yang at the National Yang-Ming University Center for Systems and Synthetic Biology.
Chief Executive Officer Su emphasized that the biotech industry differs from other industries in that it is built upon research/clinical data, from the accuracy and authenticity of which we weave a dream together, giving the industry back its expected value. In the end, he listed and shared with the audience several books that have inspired him. The most representative book among them is “The Black Swan,” which mentions that “people tend to overestimate their knowledge, and underestimate the unknown events.” To overcome this misconception, we should always remind ourselves that there is a difference between self-recognition and practical capability. Before getting involved with the biotech industry, we should, therefore, get to know about the products being researched and developed and the knowledge other than the products themselves to clearly grasp the whole biotech industrial trends.